Cargando…

Recent Advances in the Non-invasive Diagnosis of Renal Osteodystrophy

Chronic kidney disease–mineral and bone disorder (CKD-MBD) is the term used to describe a constellation of biochemical abnormalities, bone disturbances that may lead to fractures, and extraskeletal calcification in soft tissues and arteries seen in CKD. This review focuses on the non-invasive diagno...

Descripción completa

Detalles Bibliográficos
Autores principales: Moorthi, Ranjani N, Moe, Sharon M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3805700/
https://www.ncbi.nlm.nih.gov/pubmed/23802194
http://dx.doi.org/10.1038/ki.2013.254
_version_ 1782477899083808768
author Moorthi, Ranjani N
Moe, Sharon M
author_facet Moorthi, Ranjani N
Moe, Sharon M
author_sort Moorthi, Ranjani N
collection PubMed
description Chronic kidney disease–mineral and bone disorder (CKD-MBD) is the term used to describe a constellation of biochemical abnormalities, bone disturbances that may lead to fractures, and extraskeletal calcification in soft tissues and arteries seen in CKD. This review focuses on the non-invasive diagnosis of renal osteodystrophy, the term used exclusively to define the bone pathology associated with CKD. Transiliac bone biopsy and histomorphometry with double-labeled tetracycline or its derivatives remains the gold standard for diagnosis of renal osteodystrophy. However, histomorphometry provides a “window” into bone only at a single point in time, is invasive, and not practical to study continuous changes in bone morphology. Further, CKD is a risk factor for fractures, and the etiology is multi-factorial and not fully explained by histomorphometry findings alone. The propensity of a bone to fracture is determined by bone strength, which is affected by bone mass and bone quality; the latter is a term used to describe the structure and composition of bone. Bone quantity is traditionally assessed by Dual X-ray Absorptiometry (DXA) and CT based methods. Bone quality is more difficult to assess non- invasively, but newer techniques are emerging and described in this review. Ultimately, the optimal diagnostic strategy for renal osteodystrophy may be a combination of multiple imaging techniques and biomarkers that are specific to each gender and race in CKD with a goal of predicting fracture risk and optimizing therapy.
format Online
Article
Text
id pubmed-3805700
institution National Center for Biotechnology Information
language English
publishDate 2013
record_format MEDLINE/PubMed
spelling pubmed-38057002014-05-01 Recent Advances in the Non-invasive Diagnosis of Renal Osteodystrophy Moorthi, Ranjani N Moe, Sharon M Kidney Int Article Chronic kidney disease–mineral and bone disorder (CKD-MBD) is the term used to describe a constellation of biochemical abnormalities, bone disturbances that may lead to fractures, and extraskeletal calcification in soft tissues and arteries seen in CKD. This review focuses on the non-invasive diagnosis of renal osteodystrophy, the term used exclusively to define the bone pathology associated with CKD. Transiliac bone biopsy and histomorphometry with double-labeled tetracycline or its derivatives remains the gold standard for diagnosis of renal osteodystrophy. However, histomorphometry provides a “window” into bone only at a single point in time, is invasive, and not practical to study continuous changes in bone morphology. Further, CKD is a risk factor for fractures, and the etiology is multi-factorial and not fully explained by histomorphometry findings alone. The propensity of a bone to fracture is determined by bone strength, which is affected by bone mass and bone quality; the latter is a term used to describe the structure and composition of bone. Bone quantity is traditionally assessed by Dual X-ray Absorptiometry (DXA) and CT based methods. Bone quality is more difficult to assess non- invasively, but newer techniques are emerging and described in this review. Ultimately, the optimal diagnostic strategy for renal osteodystrophy may be a combination of multiple imaging techniques and biomarkers that are specific to each gender and race in CKD with a goal of predicting fracture risk and optimizing therapy. 2013-06-26 2013-11 /pmc/articles/PMC3805700/ /pubmed/23802194 http://dx.doi.org/10.1038/ki.2013.254 Text en http://www.nature.com/authors/editorial_policies/license.html#terms Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Moorthi, Ranjani N
Moe, Sharon M
Recent Advances in the Non-invasive Diagnosis of Renal Osteodystrophy
title Recent Advances in the Non-invasive Diagnosis of Renal Osteodystrophy
title_full Recent Advances in the Non-invasive Diagnosis of Renal Osteodystrophy
title_fullStr Recent Advances in the Non-invasive Diagnosis of Renal Osteodystrophy
title_full_unstemmed Recent Advances in the Non-invasive Diagnosis of Renal Osteodystrophy
title_short Recent Advances in the Non-invasive Diagnosis of Renal Osteodystrophy
title_sort recent advances in the non-invasive diagnosis of renal osteodystrophy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3805700/
https://www.ncbi.nlm.nih.gov/pubmed/23802194
http://dx.doi.org/10.1038/ki.2013.254
work_keys_str_mv AT moorthiranjanin recentadvancesinthenoninvasivediagnosisofrenalosteodystrophy
AT moesharonm recentadvancesinthenoninvasivediagnosisofrenalosteodystrophy